Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: Relevance to Parkinson's disease
- 16 February 2005
- journal article
- research article
- Published by Elsevier BV in Neurobiology of Disease
- Vol. 19 (1-2), 96-107
- https://doi.org/10.1016/j.nbd.2004.11.009
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Expression of cannabinoid CB 1 receptor mRNA in basal ganglia of normal and parkinsonian human brainJournal of Neural Transmission, 2003
- Antioxidants as treatment for neurodegenerative disordersExpert Opinion on Investigational Drugs, 2002
- Cannabinoids Protect Astrocytes from Ceramide-induced Apoptosis through the Phosphatidylinositol 3-Kinase/Protein Kinase B PathwayJournal of Biological Chemistry, 2002
- Stimulation of cannabinoid receptors reduces levodopa‐induced dyskinesia in the MPTP‐lesioned nonhuman primate model of Parkinson's diseaseMovement Disorders, 2002
- Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problemsJournal of Neural Transmission, 2002
- Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosetsEuropean Journal of Neuroscience, 2001
- Perinatal Δ9-Tetrahydrocannabinol Exposure Did Not Alter Dopamine Transporter and Tyrosine Hydroxylase mRNA Levels in Midbrain Dopaminergic Neurons of Adult Male and Female RatsNeurotoxicology and Teratology, 1998
- Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal functionBrain Research, 1995
- Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicingNature, 1984
- Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue.The Journal of cell biology, 1980